Citations (116)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
Qianqian Zhou, Shengru Zhou, Huizi Xiong, Jianqiu Yang, Ziliang Yang, Naihui Zhou, Jinzhu Mao & Min Li. (2023) A Case of Paradoxical Reactions to Biologic Therapy for Psoriasis. Clinical, Cosmetic and Investigational Dermatology 16, pages 1493-1497.
Read now
Read now
Yafei Liu & Fei Liao. (2023) Vaccination therapy for inflammatory bowel disease. Human Vaccines & Immunotherapeutics 19:2.
Read now
Read now
A Al-Janabi & Z Z N Yiu. (2022) Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management. Psoriasis: Targets and Therapy 12, pages 1-14.
Read now
Read now
Angelo Ruggiero, Matteo Megna, Gabriella Fabbrocini, Luigi Fornaro & Alessia Villani. (2022) Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge. Expert Opinion on Drug Safety 21:10, pages 1249-1257.
Read now
Read now
Claudio Conforti, Caterina Dianzani, Iris Zalaudek, Michele Cicala, Paolo Persichetti, Roberta Giuffrida, Silviu-Horia Morariu & Nicoleta Neagu. (2022) Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review. Journal of Dermatological Treatment 33:3, pages 1279-1286.
Read now
Read now
Zara Ali, Raymond Matthews, Ali Al-Janabi & Richard B Warren. (2021) Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis. Expert Review of Clinical Immunology 17:10, pages 1073-1081.
Read now
Read now
Stephanie Keeling & Walter P. Maksymowych. (2021) JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. Expert Review of Clinical Immunology 17:7, pages 701-715.
Read now
Read now
Kentaro Noda, Yoshiki Okita, Yuki Mizutani, Naohiro Sugitani, Yasuo Suzuki, Masato Kusunoki & Ayako Nakajima. (2021) Risk factors for arthropathy in patients with ulcerative colitis after total colectomy. Modern Rheumatology 31:2, pages 468-473.
Read now
Read now
Helena Iznardo & Lluís Puig. (2020) The safety of brodalumab for the treatment of psoriasis. Expert Opinion on Drug Safety 19:4, pages 365-372.
Read now
Read now
Shao-Hsuan Hsu & Tsen-Fang Tsai. (2020) Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis. Expert Review of Clinical Pharmacology 13:3, pages 211-232.
Read now
Read now
Lluís Puig. (2020) The safety of ixekizumab in psoriasis drug therapy. Expert Opinion on Drug Safety 19:2, pages 117-130.
Read now
Read now
Karen Ly, Mary P. Smith, Quinn Thibodeaux, Vidhatha Reddy, Wilson Liao & Tina Bhutani. (2019) Anti IL-17 in psoriasis. Expert Review of Clinical Immunology 15:11, pages 1185-1194.
Read now
Read now
S. D’Adamio, D. Silvaggio, P. Lombardo, L. Bianchi, M. Talamonti & M. Galluzzo. (2019) The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis. Expert Opinion on Drug Safety 18:11, pages 1031-1041.
Read now
Read now
Chuanlan Gu & Junyi Yang. (2019) Risankizumab for the treatment of psoriasis. Expert Review of Clinical Pharmacology 12:9, pages 851-857.
Read now
Read now
Sree S. Kolli, Anna L. Kepley, Abigail Cline & Steven R. Feldman. (2019) A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data. Expert Opinion on Drug Safety 18:6, pages 523-536.
Read now
Read now
Rodney Sinclair & Vetrichevvel Thirthar Palanivelu. (2019) Tildrakizumab for the treatment of psoriasis. Expert Review of Clinical Immunology 15:1, pages 5-12.
Read now
Read now
Annika Silfvast-Kaiser, So Yeon Paek & Alan Menter. (2019) Anti-IL17 therapies for psoriasis. Expert Opinion on Biological Therapy 19:1, pages 45-54.
Read now
Read now
Todd Wechter, Abigail Cline & Steven R Feldman. (2018) Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab. Therapeutics and Clinical Risk Management 14, pages 1489-1497.
Read now
Read now
Katherine M. Stiff, Katelyn R. Glines, Caroline L. Porter, Abigail Cline & Steven R. Feldman. (2018) Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis. Expert Review of Clinical Pharmacology 11:12, pages 1209-1218.
Read now
Read now
Daniel J. No, Mina Amin, Tina Bhutani & Jashin J. Wu. (2018) A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis. Journal of Dermatological Treatment 29:5, pages 467-474.
Read now
Read now
Mina Amin, Kavita Darji, Daniel J. No, Tina Bhutani & Jashin J. Wu. (2018) Review of IL-17 inhibitors for psoriasis. Journal of Dermatological Treatment 29:4, pages 347-352.
Read now
Read now
Articles from other publishers (95)
Saeideh Sadat Shobeiri, Mohammadreza Dashti, Safoora Pordel, MohammadAli Rezaee, Navideh Haghnavaz, Malihe Moghadam, Bahareh Ansari & Mojtaba Sankian. (2023) Topical anti-TNF-a ssDNA aptamer decreased the imiquimod induced psoriatic inflammation in BALB/c mice. Cytokine 172, pages 156406.
Crossref
Crossref
Yangke Cai, Xuan Jia, Liyi Xu, Hanwen Chen, Siyuan Xie & Jianting Cai. (2023) Interleukin-17 and inflammatory bowel disease: a 2-sample Mendelian randomization study. Frontiers in Immunology 14.
Crossref
Crossref
Xenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, Marina Magrey, Walter P Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, Carmen Fleurinck, Alicia M Ellis, Thomas Vaux, Julie Shepherd-Smith, Alexander Marten & Lianne S Gensler. (2023) Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Annals of the Rheumatic Diseases, pages ard-2023-224803.
Crossref
Crossref
Ruchen Yao & Jun Shen. (2023) Chaperone‐mediated autophagy: Molecular mechanisms, biological functions, and diseases. MedComm 4:5.
Crossref
Crossref
Andrea S. Kreienbuehl & Luc Biedermann. (2023) Morbus Crohn UpdateMaladie de Crohn – une mise à jourMorbo di Crohn – un aggiornamento. Schweizer Gastroenterologie 4:2, pages 48-63.
Crossref
Crossref
Hui Cao, Jun Diao, Huosheng Liu, Suxian Liu, Jun Liu, Jianye Yuan & Jiang Lin. (2023) The Pathogenicity and Synergistic Action of Th1 and Th17 Cells in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases 29:5, pages 818-829.
Crossref
Crossref
Tumay Ak, Sera Nur Yucesoy Temiz, Meliksah Taner, Ali Yagiz Ayla, Ahmet Atıl Aygun, Burhan Engin, Gunay Can & Serdal Ugurlu. (2023)
Effectiveness of
anti‐interleukin
‐23 therapy in psoriatic arthritis: A pilot prospective real‐world study
. International Journal of Rheumatic Diseases 26:5, pages 878-884.
Crossref
Crossref
Agata Krawczyk, Barbara Strzałka-Mrozik, Karol Juszczyk, Magdalena Kimsa-Dudek, Dominika Wcisło-Dziadecka & Joanna Gola. (2023) The MAP2K2 Gene as Potential Diagnostic Marker in Monitoring
Adalimumab Therapy of Psoriatic Arthritis. Current Pharmaceutical Biotechnology 24:2, pages 330-340.
Crossref
Crossref
Alina Mihaela Morosanu, Ioana Ruxandra Mihai & Ioana Irina Rezus. (2022) New onset severe ulcerative colitis following Ixekizumab therapy. Archive of Clinical Cases 9:4, pages 173-176.
Crossref
Crossref
Saeideh Sadat Shobeiri, Kazem Mashayekhi, Motahareh Khorrami, Malihe Moghadam & Mojtaba Sankian. (2022) Selection and characterization of a new human Interleukin-17A blocking DNA aptamer using protein-SELEX. Biochemical and Biophysical Research Communications 637, pages 32-39.
Crossref
Crossref
Anastasia Drakos & Ronald Vender. (2022) A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians. Dermatology and Therapy 12:12, pages 2715-2730.
Crossref
Crossref
Yana Yang, Wenhui Qi, Yanyan Zhang, Ruining Wang, Mingyue Bao, Mengyuan Tian, Xing Li & Yuan Zhang. (2022) Natural Compound 2,2′,4′-Trihydroxychalcone Suppresses T Helper 17 Cell Differentiation and Disease Progression by Inhibiting Retinoid-Related Orphan Receptor Gamma T. International Journal of Molecular Sciences 23:23, pages 14547.
Crossref
Crossref
Eugenia Veronica Di Brizzi, Annachiara Rocco, Graziella Babino, Dario Buononato, Giuseppe Argenziano & Anna Balato. (2022) Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs. Biomedicines 10:11, pages 2968.
Crossref
Crossref
Li Xi, Sandra Garcet, Zhan Ye, Kenneth Hung, Mina Hassan-Zahraee, Elizabeth Kieras, James G. Krueger, Craig Hyde & Elena Peeva. (2022) A shared tissue transcriptome signature and pathways in psoriasis and ulcerative colitis. Scientific Reports 12:1.
Crossref
Crossref
Khalid A. Alnaqbi, Suad Hannawi, Rajaie Namas, Waleed Alshehhi, Humeira Badsha & Jamal Al‐Saleh. (2022) Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates. International Journal of Rheumatic Diseases 25:10, pages 1107-1122.
Crossref
Crossref
Irina Turchin & Marc Bourcier. (2022) The Role of Interleukins in the Pathogenesis of Dermatological Immune-Mediated Diseases. Advances in Therapy 39:10, pages 4474-4508.
Crossref
Crossref
Annkathrin Knauss, Michael Gabel, Markus F. Neurath & Benno Weigmann. (2022) The Memory T Cell “Communication Web” in Context with Gastrointestinal Disorders—How Memory T Cells Affect Their Surroundings and How They Are Influenced by It. Cells 11:18, pages 2780.
Crossref
Crossref
E. V. Bolotova, K. A. Yumukyan, A. V. Dudnikova & I. V. Gilevich. (2022) Diagnostic power of laboratory methods for assessing ulcerative colitis severity: A prospective comparative study. Kuban Scientific Medical Bulletin 29:3, pages 14-29.
Crossref
Crossref
Ana Ion, Alexandra Maria Dorobanțu, Liliana Gabriela Popa, Mara Mădălina Mihai & Olguța Anca Orzan. (2022) Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases. Biology 11:6, pages 808.
Crossref
Crossref
Nika Hlaca, Tina Zagar, Marija Kastelan, Ines Brajac & Larisa Prpic‐Massari. (2022) Secukinumab‐induced scar sarcoidosis in a patient with plaque psoriasis. Australasian Journal of Dermatology 63:2.
Crossref
Crossref
Dimitri Luz Felipe da Silva, Elisa Nunes Secamilli, Mariana Valbon Beleli, Juliana Yumi Massuda, Andrea F.E.C. Franca & Renata F. Magalhães. (2022) Immunobiologicals in dermatology. Anais Brasileiros de Dermatologia 97:3, pages 275-283.
Crossref
Crossref
Laura Țiburcă, Marius Bembea, Dana Carmen Zaha, Alexandru Daniel Jurca, Cosmin Mihai Vesa, Ioana Adela Rațiu & Claudia Maria Jurca. (2022) The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases. Current Issues in Molecular Biology 44:5, pages 1851-1866.
Crossref
Crossref
Dan Wang, Tiehua Zhang, Hongwei Hao, Hongxing Zhang, Haiqing Ye & Changhui Zhao. (2022) Probiotic Properties of a Spaceflight-induced Mutant Lactobacillus Plant-
arum SS18-50 in Mice. Endocrine, Metabolic & Immune Disorders - Drug Targets 22:5, pages 525-531.
Crossref
Crossref
Jennifer Ornelas & Kelly M. Cordoro. (2022) Clinical Decisions in Pediatric Psoriasis. Dermatologic Clinics 40:2, pages 145-166.
Crossref
Crossref
Snehali Majumder, Uday Nagesh Shivaji, Rangarajan Kasturi, Alben Sigamani, Subrata Ghosh & Marietta Iacucci. (2022) Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives. World Journal of Gastrointestinal Oncology 14:3, pages 547-567.
Crossref
Crossref
Anna Nemirovsky, Karny Ilan, Livnat Lerner, Liel Cohen-Lavi, Doron Schwartz, Ganit Goren, Ruslan Sergienko, Dan Greenberg, Vered Slonim-Nevo, Orly Sarid, Michael Friger, Shirley Regev, Shmuel Odes, Tomer Hertz & Alon Monsonego. (2022) Brain-immune axis regulation is responsive to cognitive behavioral therapy and mindfulness intervention: Observations from a randomized controlled trial in patients with Crohn's disease. Brain, Behavior, & Immunity - Health 19, pages 100407.
Crossref
Crossref
Kate E Findeisen & Andrew JK Östör. (2022) The Role of Interleukin-23 Inhibition in the Treatment of Psoriatic Arthritis. Rheumatology 1:1, pages 18.
Crossref
Crossref
Tetsuo Hasegawa & Masaru Ishii. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
422
426
.
Fernando Valenzuela & Rodrigo Flores. 2022. Textbook of Dermatologic Ultrasound. Textbook of Dermatologic Ultrasound
345
365
.
Yu-Yi Yuan, Yu-Jin Liu & Heng Fan. (2021) New progress in research of Th17 cells and related cytokines in inflammatory bowel disease. World Chinese Journal of Digestology 29:24, pages 1402-1409.
Crossref
Crossref
Istvan Fedor, Eva Zold & Zsolt Barta. (2021) Temporal Relationship of Extraintestinal Manifestations in Inflammatory Bowel Disease. Journal of Clinical Medicine 10:24, pages 5984.
Crossref
Crossref
Xin Mu, John Fardy, Stephanie Reid & Julia Trahey. (2021) Severe drug-associated colitis with Crohn’s features in setting of ixekizumab therapy for chronic plaque psoriasis. BMC Gastroenterology 21:1.
Crossref
Crossref
Ailia K. Ali, Arman Torosian, Caroline Porter, Richard S. Bloomfeld & Steven R. Feldman. (2021) New onset inflammatory bowel disease in patient treated with secukinumab: Case report and review of literature. Dermatologic Therapy 34:6.
Crossref
Crossref
Gerhard Rogler, Abha Singh, Arthur Kavanaugh & David T. Rubin. (2021) Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology 161:4, pages 1118-1132.
Crossref
Crossref
Xuhui Tong, Yuanyuan Zheng, Yu Li, Yongjian Xiong & Dapeng Chen. (2021) Soluble ligands as drug targets for treatment of inflammatory bowel disease. Pharmacology & Therapeutics 226, pages 107859.
Crossref
Crossref
Qi Yin, Xuelei Pi, Yuanyuan Jiang, Guiping Ren, Zhihang Liu, Han Liu, Mengxia Wang, Wenying Sun, Siyu Li, Zhenqiu Gao, Deshan Li & Jiechao Yin. (2021) An immuno-blocking agent targeting IL-1β and IL-17A reduces the lesion of DSS-induced ulcerative colitis in mice. Inflammation 44:5, pages 1724-1736.
Crossref
Crossref
Guanqun Li, Hongze Chen, Liwei Liu, Peng Xiao, Yu Xie, Xinglong Geng, Tao Zhang, Yang Zhang, Tianqi Lu, Hongtao Tan, Le Li & Bei Sun. (2021) Role of Interleukin-17 in Acute Pancreatitis. Frontiers in Immunology 12.
Crossref
Crossref
Neil H. Shear, Keith A. Betts, Ahmed M. Soliman, Avani Joshi, Yan Wang, Jing Zhao, Paolo Gisondi, Ranjeeta Sinvhal & April W. Armstrong. (2021) Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. Journal of the American Academy of Dermatology 85:3, pages 572-581.
Crossref
Crossref
Shadi Hamdeh, Dejan Micic & Stephen Hanauer. (2021) Drug-Induced Colitis. Clinical Gastroenterology and Hepatology 19:9, pages 1759-1779.
Crossref
Crossref
Kristian ReichRichard B. WarrenMark LebwohlMelinda GooderhamBruce StroberRichard G. LangleyCarle PaulDirk De CuyperVeerle VanvoordenCynthia MaddenChristopher CioffiLuke PetersonAndrew Blauvelt. (2021) Bimekizumab versus Secukinumab in Plaque Psoriasis. New England Journal of Medicine 385:2, pages 142-152.
Crossref
Crossref
S. Ribero, A. Ramondetta, G. Fabbrocini, V. Bettoli, C. Potenza, A. Chiricozzi, M. Licciardello, A.V. Marzano, L. Bianchi, G. Rozzo, L. Fania, C. Marasca, G. Odorici, A. Mambrin, C. Moltrasio, R.D. Caposiena Caro, N. Skroza, P. Quaglino, N. Siliquini & P. Dapavo. (2021) Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting. Journal of the European Academy of Dermatology and Venereology 35:7.
Crossref
Crossref
Nadine Petitpain, Ferdinando D’Amico, Melissa Yelehe‐Okouma, Jean‐Yves Jouzeau, Patrick Netter, Laurent Peyrin‐Biroulet & Pierre Gillet. (2021) IL‐17 Inhibitors and Inflammatory Bowel Diseases: A Postmarketing Study in Vigibase. Clinical Pharmacology & Therapeutics 110:1, pages 159-168.
Crossref
Crossref
Marcello Candelli, Laura Franza, Giulia Pignataro, Veronica Ojetti, Marcello Covino, Andrea Piccioni, Antonio Gasbarrini & Francesco Franceschi. (2021) Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases. International Journal of Molecular Sciences 22:12, pages 6242.
Crossref
Crossref
Cécile Fermon, Mathieu Gerfaud-Valentin, François Durupt & Pascal Sève. (2021) Aphthous Stomatitis in a Man with Psoriatic Arthritis. The American Journal of Medicine 134:6, pages 749-750.
Crossref
Crossref
Thomas Greuter, Florian Rieder, Torsten Kucharzik, Laurent Peyrin-Biroulet, Alain M Schoepfer, David T Rubin & Stephan R Vavricka. (2021) Emerging treatment options for extraintestinal manifestations in IBD. Gut 70:4, pages 796-802.
Crossref
Crossref
M. Nogueira, R.B. Warren & T. Torres. (2020) Risk of tuberculosis reactivation with interleukin (IL)‐17 and IL‐23 inhibitors in psoriasis – time for a paradigm change. Journal of the European Academy of Dermatology and Venereology 35:4, pages 824-834.
Crossref
Crossref
Dennis McGonagle, Abdulla Watad, Kassem Sharif & Charlie Bridgewood. (2021) Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis. Frontiers in Immunology 12.
Crossref
Crossref
Vatsalya Vatsalya, Fengyuan Li, Jane Frimodig, Khushboo S. Gala, Shweta Srivastava, Maiying Kong, Vijay A. Ramchandani, Wenke Feng, Xiang Zhang & Craig J. McClain. (2021) Repurposing Treatment of Wernicke–Korsakoff Syndrome for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-Vitro Evidence and Pharmacokinetic Profile. Frontiers in Pharmacology 11.
Crossref
Crossref
S. Afach, A. Chaimani, T. Evrenoglou, L. Penso, E. Brouste, E. Sbidian & L. Le Cleach. (2020) Meta‐analysis results do not reflect the real safety of biologics in psoriasis*. British Journal of Dermatology 184:3, pages 415-424.
Crossref
Crossref
Colm Kirby, Darragh Herlihy, Lindsey Clarke & Ronan Mullan. (2021) Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis. BMJ Case Reports 14:2, pages e240615.
Crossref
Crossref
Dennis McGonagle, Abdulla Watad, Kassem Sharif & Charlie Bridgewood. (2021) Warum die Hemmung von IL-23 bei ankylosierender Spondylitis nicht wirksam war. Kompass Autoimmun 3:3, pages 100-107.
Crossref
Crossref
Jemima Ho, Giorgio Camilli, James S. Griffiths, Jonathan P. Richardson, Nessim Kichik & Julian R. Naglik. (2020)
Candida albicans
and candidalysin in inflammatory disorders and cancer
. Immunology 162:1, pages 11-16.
Crossref
Crossref
R.B. Warren, A. Blauvelt, Y. Poulin, S. Beeck, M. Kelly, T. Wu, Z. Geng & C. Paul. (2020) Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*. British Journal of Dermatology 184:1, pages 50-59.
Crossref
Crossref
Jingyi Ju, Yuanyuan Dai, Jiaolan Yang, Changqin Liu, Li Fan, Lijin Feng, Binghui Zhao, Meiying Zeng, Zhanju Liu & Xiaomin Sun. (2020) Crohn’s disease exacerbated by IL-17 inhibitors in patients with psoriasis: a case report. BMC Gastroenterology 20:1.
Crossref
Crossref
Raquel Rivera, Manuel Velasco, David Vidal, J. Manuel Carrascosa, Esteban Daudén, E Vilarrasa, Jaime Notario, Ricardo Ruíz‐Villaverde, Ignacio Yanguas, Francisco Javier García‐Latasa, Marta Ferrán, Anna Lázaro‐Simó, Pablo Cueva, Laura Salgado‐Boquete & Isabel Belinchón. (2020) The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study. Dermatologic Therapy 33:6.
Crossref
Crossref
Sara Salvador-Martín, Ferrán Bossacoma, Gemma Pujol-Muncunill, Víctor Manuel Navas-López, Carmen Gallego-Fernández, Javier Viada, Rosana Muñoz-Codoceo, Lorena Magallares, Eva Martínez-Ojinaga, Ana Moreno-Álvarez, Alfonso Solar-Boga, Oscar Segarra, Susana Clemente, Alejandro Rodriguez-Martinez, Concepción Alvarez-Vayo, Inés Loverdos, Vicente Merino-Bohórquez, María J. Balboa-Vega, José A. Blanca-García, María J. Fobelo, Antonio Millán-Jiménez, Ruth García-Romero, Cesar Sanchez, Mar Tolín, Rafael Gonzalez de Caldas, Francisco J. Eizaguirre, José G. Sánchez-Hernandez, Ricardo Torres-Peral, Elena Aznal, Xandra García-González, María Sanjurjo-Sáez & Luis A. López-Fernández. (2020) Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 71:4, pages 508-515.
Crossref
Crossref
Marine Fauny, David Moulin, Ferdinando D'Amico, Patrick Netter, Nadine Petitpain, Djesia Arnone, Jean-Yves Jouzeau, Damien Loeuille & Laurent Peyrin-Biroulet. (2020) Paradoxical gastrointestinal effects of interleukin-17 blockers. Annals of the Rheumatic Diseases 79:9, pages 1132-1138.
Crossref
Crossref
J.L.W. Lambert, S. Segaert, P.D. Ghislain, T. Hillary, A. Nikkels, F. Willaert, J. Lambert & R. Speeckaert. (2020) Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2). Journal of the European Academy of Dermatology and Venereology 34:9, pages 1914-1923.
Crossref
Crossref
Muhammad Shahid Nadeem, Vikas Kumar, Fahad A. Al-Abbasi, Mohammad Amjad Kamal & Firoz Anwar. (2020) Risk of colorectal cancer in inflammatory bowel diseases. Seminars in Cancer Biology 64, pages 51-60.
Crossref
Crossref
Paulina Krawiec & Elżbieta Pac-Kożuchowska. (2020) Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease. Scientific Reports 10:1.
Crossref
Crossref
K. M. Darch, T. L. Holland & L. J. Spelman. (2020) Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23. Case Reports in Medicine 2020, pages 1-6.
Crossref
Crossref
Ze-Yu Wu, Li-Xuan Sang & Bing Chang. (2020) Isoflavones and inflammatory bowel disease. World Journal of Clinical Cases 8:11, pages 2081-2091.
Crossref
Crossref
Johan Burisch, Wolfgang Eigner, Stefan Schreiber, Daniel Aletaha, Wolfgang Weninger, Michael Trauner, Walter Reinisch & Neeraj Narula. (2020) Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. PLOS ONE 15:5, pages e0233781.
Crossref
Crossref
Lourdes M. Perez-Chada & Joseph F. Merola. (2020) Comorbidities associated with psoriatic arthritis: Review and update. Clinical Immunology 214, pages 108397.
Crossref
Crossref
Gareth M. Hynes & Timothy S.C. Hinks. (2020) The role of interleukin-17 in asthma: a protective response?. ERJ Open Research 6:2, pages 00364-2019.
Crossref
Crossref
A. S. W. Lee, N. J. Levell, S. N. Shah, K. Gaffney & M. A. W. Tremelling. (2019)
Severe colitis complicating secukinumab (Cosentyx
®
) therapy
. Clinical and Experimental Dermatology 45:3, pages 344-345.
Crossref
Crossref
Lorenzo Bertani, Luca Antonioli, Matteo Fornai, Gherardo Tapete, Giovanni Baiano Svizzero, Santino Marchi, Corrado Blandizzi & Francesco Costa. (2020) Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases. Minerva Gastroenterologica e Dietologica 65:4.
Crossref
Crossref
Caroline Di Jiang & Tim Raine. (2020) IBD considerations in spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease 12, pages 1759720X2093941.
Crossref
Crossref
Roberto Esquivel-García, Michael Ayiania, Nehal Abu-Lail, Joel E. López-Meza, Rosa E. del Río, Manuel García-Pérez, Alejandra Ochoa-Zarzosa & Martha-Estrella García-Pérez. (2020) Pyrolytic oils from Amphipterygium adstringens bark inhibit IL-8 production of IL-17-stimulated HaCaT keratinocytes. Journal of Analytical and Applied Pyrolysis 145, pages 104749.
Crossref
Crossref
Chen-Yu Wu, Hsien-Yi Chiu & Tsen-Fang Tsai. (2019) The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies. PLOS ONE 14:12, pages e0225112.
Crossref
Crossref
Tian Niu, Lu Cheng, Hanying Wang, Shaopin Zhu, Xiaolu Yang, Kun Liu, Huiyi Jin & Xun Xu. (2019) KS23, a novel peptide derived from adiponectin, inhibits retinal inflammation and downregulates the proportions of Th1 and Th17 cells during experimental autoimmune uveitis. Journal of Neuroinflammation 16:1.
Crossref
Crossref
Matthew K. Smith, Jay Pai, Remo Panaccione, Paul Beck, Jose G. Ferraz & Humberto Jijon. (2019) Crohn’s-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report. BMC Gastroenterology 19:1.
Crossref
Crossref
Fang Liu, Seul A. Lee, Stephen M. Riordan, Li Zhang & Lixin Zhu. (2019) Effects of Anti-Cytokine Antibodies on Gut Barrier Function. Mediators of Inflammation 2019, pages 1-15.
Crossref
Crossref
Akihiro Yamada, Jingzhou Wang, Yuga Komaki, Fukiko Komaki, Dejan Micic & Atsushi Sakuraba. (2019) Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Alimentary Pharmacology & Therapeutics 50:4, pages 373-385.
Crossref
Crossref
Kristian Reich, Melinda Gooderham, Diamant Thaçi, Jeffrey J Crowley, Caitriona Ryan, James G Krueger, Tsen-Fang Tsai, Mary Flack, Yihua Gu, David A Williams, Elizabeth H Z Thompson & Carle Paul. (2019) Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. The Lancet 394:10198, pages 576-586.
Crossref
Crossref
Walter Fries, Alessandra Belvedere, Maria Cappello, Ambrogio Orlando & Gianluca Trifirò. (2019) Inflammatory Bowel Disease Onset During Secukinumab Treatment: Real Concern or Just an Expression of Dysregulated Immune Response?. Clinical Drug Investigation 39:8, pages 799-803.
Crossref
Crossref
Ted George Achufusi, Prateek S. Harnee & Sekou Rawlins. (2019) A Rare Case of New-Onset Ulcerative Colitis following Initiation of Secukinumab. Case Reports in Medicine 2019, pages 1-5.
Crossref
Crossref
Michael P. Schön. (2019) Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders. Frontiers in Immunology 10.
Crossref
Crossref
Clara Yzet, Stacy S. Tse, Maia Kayal, Robert Hirten & Jean-Frédéric Colombel. (2019) Novel Targets For Therapeutic Intervention in Inflammatory Bowel Disease. What is the Best Way to Assess the Safety Profile of a Drug?. Current Pharmaceutical Design 25:1, pages 57-63.
Crossref
Crossref
Alessandro Poggi, Roberto Benelli, Roberta Venè, Delfina Costa, Nicoletta Ferrari, Francesca Tosetti & Maria Raffaella Zocchi. (2019) Human Gut-Associated Natural Killer Cells in Health and Disease. Frontiers in Immunology 10.
Crossref
Crossref
Christine Fahim, Ben Whan Kim, Marc Bourcier, Steven Glassman, Melinda Gooderham, Lyn Guenther, Wayne Gulliver, Charles Lynde, Yves Poulin, Melanie Pratt, Neil Shear, Ronald Vender, Scott Walsh & Simone Fahim. (2019) Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study. Journal of Cutaneous Medicine and Surgery 23:3, pages 282-288.
Crossref
Crossref
C R H Hedin, S R Vavricka, A J Stagg, A Schoepfer, T Raine, L Puig, U Pleyer, A Navarini, A E van der Meulen-de Jong, J Maul, K Katsanos, A Kagramanova, T Greuter, Y González-Lama, F van Gaalen, P Ellul, J Burisch, D Bettenworth, M D Becker, G Bamias & F Rieder. (2019) The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. Journal of Crohn's and Colitis 13:5, pages 541-554.
Crossref
Crossref
Loïc Delens, Grégory Ehx, Joan Somja, Louise Vrancken, Ludovic Belle, Laurence Seidel, Céline Grégoire, Gilles Fransolet, Caroline Ritacco, Muriel Hannon, Sophie Dubois, Yves Beguin, Frédéric Baron & Sophie Servais. (2019) In Vitro Th17-Polarized Human CD4+ T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation 25:2, pages 204-215.
Crossref
Crossref
Yuanjun Li & Yedi Zhou. (2019) Interleukin-17: The Role for Pathological Angiogenesis in Ocular Neovascular Diseases. The Tohoku Journal of Experimental Medicine 247:2, pages 87-98.
Crossref
Crossref
Giovanni Adami, Kenneth G. Saag, Roland D. Chapurlat, Nuria Guañabens, Glenn Haugeberg, Willem F. Lems, Radmila Matijevic, Nicola Peel, Denis Poddubnyy & Piet Geusens. (2019) Balancing benefits and risks in the era of biologics. Therapeutic Advances in Musculoskeletal Disease 11, pages 1759720X1988397.
Crossref
Crossref
E. Liana Falcone & Steven M. Holland. 2019. NADPH Oxidases. NADPH Oxidases
573
586
.
Jobin Philipose, Youssef El Douaihy & Deeb Khouri Liliane. (2018) An Unusual Case of Bloody Diarrhea in a Young Man. Gastroenterology 155:6, pages 1695-1696.
Crossref
Crossref
Andrew Blauvelt & Andrea Chiricozzi. (2018) The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clinical Reviews in Allergy & Immunology 55:3, pages 379-390.
Crossref
Crossref
Kazuhisa Furue, Takamichi Ito & Masutaka Furue. (2018) Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis. Cytokine 111, pages 182-188.
Crossref
Crossref
M. Munera-Campos, F. Ballesca & J.M. Carrascosa. (2018) Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature. Actas Dermo-Sifiliográficas (English Edition) 109:9, pages 791-800.
Crossref
Crossref
M. Munera-Campos, F. Ballesca & J.M. Carrascosa. (2018) Reacciones paradójicas de los tratamientos biológicos utilizados en psoriasis: revisión de la literatura. Actas Dermo-Sifiliográficas 109:9, pages 791-800.
Crossref
Crossref
Hsien-Yi Chiu, Ting-Shun Wang, Po-Hua Chen, Shao-Hsuan Hsu, Ya-Chu Tsai & Tsen-Fang Tsai. (2018) Psoriasis in Taiwan: From epidemiology to new treatments. Dermatologica Sinica 36:3, pages 115-123.
Crossref
Crossref
Abigail Cline & Steven R Feldman. (2018) Risankizumab for psoriasis. The Lancet 392:10148, pages 616-617.
Crossref
Crossref
A. Egeberg, M.B. Ottosen, R. Gniadecki, S. Broesby-Olsen, T.N. Dam, L.E. Bryld, M.K. Rasmussen & L. Skov. (2018) Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. British Journal of Dermatology 178:2, pages 509-519.
Crossref
Crossref
Mina Amin, Daniel J. No, Alexander Egeberg & Jashin J. Wu. (2017) Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?. American Journal of Clinical Dermatology 19:1, pages 1-13.
Crossref
Crossref